EMed CEO: Yaccarino Navigates Industry Turbulence

In a virtual care market defined by fragmentation and fierce competition, Linda Yaccarino steps into digital health startup eMed as its new CEO at a moment of mounting pressure for the industry.

The company, a marketplace platform and intermediary for popular weight-loss drugs known as GLP-1s, is a stark contrast to Yaccarino’s former post as CEO of X, Elon Musk’s social media platform. Analysts tell ADWEEK that Yaccarino’s experience leading marketing and partnerships, including at NBCUniversal, will be crucial for eMed to find success during a turbulent time for the telehealth industry.

For one, consumer demand for GLP-1 drugs like Ozempic and Wegovy has drawn a flood of new entrants. Telehealth companies like Hims & Hers Health and Ro have expanded their services to include weight-loss drugs, alongside giants like Amazon. Meanwhile, the FDA has cracked down on copycats of Ozempic and Zepbound, two leading GLP-1 drugs, affecting many of these startupswhich relied on cheaper alternatives to name brand weight-loss drugs.

That crowding is making differentiation difficult, especially as consumers increasingly prioritize access, conveniences, and cost over clinical expertise.

“Unlike established companies such as Claritev, Noom, and others, eMed doesn’t currently have a deep existing customer base and will need to build from the ground up,” said Aaron DeGagne, senior analyst for healthcare at PitchBook. He noted that Yaccarino may need to lean heavily on her personal relationships with employers from her advertising career to gain traction. The startup, still a relatively small operation, will also likely need fresh funding to hit its growth targets, he added.

“I’m a bit skeptical Yaccarino can lead eMed to become a major player in the space in a short time frame, considering the tough competition. They are operating in a high-demand market and could find success as a company on a smaller scale,” DeGagne said.

According to Chris Beland, a vp and analyst at Gartner, Yaccarino’s experience in marketing strategy, product positioning, brand positioning, and influencer strategy will be necessary for eMed to find position in this crowded market. “You’re seeing multiple sub-sectors start to pivot into this space. It’s just going to put a lot of pressure on new and existing competitors,” he said.

Consumers are increasingly comfortable fragmenting their care across multiple providers, Beland said, with virtual care platforms capturing the high demand for services like weight loss or hair treatment, alongside other personalized care.

eMed did not respond to requests for comment.

A $100 billion market

Yaccarino’s new job signals eMed’s ambitions to compete in this high-growth space. The GLP-1 market is projected to reach at least $100 billion in the next five years, according to J.P. Morgan. Demand for drugs like Novo Nordisk’s Ozempic and Wegovy or Eli Lilly’s Zepbound has also created a booming market for lower cost, compounded alternatives.